Northern Trust Corp Aptinyx Inc. Transaction History

Northern Trust Corp

  • $586 Billion
  • Q2 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.12 - $0.69 $9,173 - $52,747
-76,445 Reduced 50.94%
73,623 $8,000
Q3 2022

Nov 14, 2022
SELL
$0.35 - $0.72 $20,368 - $41,901
-58,197 Reduced 27.94%
150,068 $56,000
Q2 2022

Aug 12, 2022
SELL
$0.38 - $2.58 $4,344 - $29,497
-11,433 Reduced 5.2%
208,265 $116,000
Q1 2022

May 13, 2022
BUY
$2.27 - $3.62 $334,500 - $533,432
147,357 Added 203.7%
219,698 $498,000
Q3 2021

Nov 15, 2021
SELL
$2.21 - $2.89 $258,572 - $338,132
-117,001 Reduced 61.79%
72,341 $169,000
Q2 2021

Aug 13, 2021
SELL
$2.39 - $3.5 $643,842 - $942,865
-269,390 Reduced 58.72%
189,342 $535,000
Q1 2021

May 12, 2021
BUY
$2.86 - $4.33 $271,170 - $410,548
94,815 Added 26.05%
458,732 $1.38 Million
Q4 2020

Feb 11, 2021
BUY
$2.93 - $4.3 $223,939 - $328,649
76,430 Added 26.59%
363,917 $1.26 Million
Q3 2020

Nov 16, 2020
SELL
$3.05 - $4.99 $27,742 - $45,389
-9,096 Reduced 3.07%
287,487 $971,000
Q2 2020

Aug 14, 2020
BUY
$1.99 - $4.4 $523,121 - $1.16 Million
262,875 Added 779.86%
296,583 $1.24 Million
Q1 2020

May 14, 2020
BUY
$1.81 - $5.03 $20,063 - $55,757
11,085 Added 49.0%
33,708 $73,000
Q3 2019

Nov 13, 2019
SELL
$3.0 - $4.08 $363,681 - $494,606
-121,227 Reduced 84.27%
22,623 $79,000
Q2 2019

Aug 13, 2019
SELL
$2.95 - $4.38 $23,189 - $34,431
-7,861 Reduced 5.18%
143,850 $480,000
Q1 2019

May 13, 2019
BUY
$3.99 - $19.33 $2,070 - $10,032
519 Added 0.34%
151,711 $615,000
Q4 2018

Feb 12, 2019
BUY
$16.15 - $28.93 $11,337 - $20,308
702 Added 0.47%
151,192 $2.5 Million
Q3 2018

Nov 14, 2018
BUY
$20.21 - $31.85 $2.79 Million - $4.39 Million
137,931 Added 1098.26%
150,490 $4.36 Million
Q2 2018

Sep 18, 2018
BUY
$19.83 - $24.17 $249,044 - $303,551
12,559 New
12,559 $304,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email